{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T01:11:49Z","timestamp":1788311509668,"version":"build-2803163510"},"reference-count":107,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s40272-025-00688-4","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T03:40:19Z","timestamp":1742614819000},"page":"449-463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Emerging Treatments in Neonatal Fungal Infections: Progress and Prospects"],"prefix":"10.1007","volume":"27","author":[{"given":"Lucy","family":"Eletel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talia","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory L.","family":"Kearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"688_CR1","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fimmu.2017.00281","volume":"8","author":"C Michalski","year":"2017","unstructured":"Michalski C, Kan B, Lavoie PM. Antifungal immunological defenses in newborns. Front Immunol. 2017;8:281. https:\/\/doi.org\/10.3389\/fimmu.2017.00281.","journal-title":"Front Immunol"},{"issue":"4","key":"688_CR2","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.pedneo.2015.09.007","volume":"57","author":"F Cortese","year":"2016","unstructured":"Cortese F, Scicchitano P, Gesualdo M, Filaninno A, De Giorgi E, Schettini F, et al. Early and late infections in newborns: where do we stand? A review. Pediatr Neonatol. 2016;57(4):265\u201373. https:\/\/doi.org\/10.1016\/j.pedneo.2015.09.007.","journal-title":"Pediatr Neonatol"},{"issue":"6","key":"688_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","volume":"45","author":"R Bellmann","year":"2017","unstructured":"Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737\u201379. https:\/\/doi.org\/10.1007\/s15010-017-1042-z.","journal-title":"Infection"},{"issue":"9","key":"688_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","volume":"20","author":"MC Fisher","year":"2022","unstructured":"Fisher MC, Alastruey-Izquierdo A, Berman J, Bicanic T, Bignell EM, Bowyer P, et al. Tackling the emerging threat of antifungal resistance to human health. Nat Rev Microbiol. 2022;20(9):557\u201371. https:\/\/doi.org\/10.1038\/s41579-022-00720-1.","journal-title":"Nat Rev Microbiol"},{"issue":"4","key":"688_CR5","doi-asserted-by":"publisher","first-page":"314","DOI":"10.4103\/0975-7406.72131","volume":"2","author":"A Jain","year":"2010","unstructured":"Jain A, Jain S, Rawat S. Emerging fungal infections among children: a review on its clinical manifestations, diagnosis, and prevention. J Pharm Bioallied Sci. 2010;2(4):314\u201320. https:\/\/doi.org\/10.4103\/0975-7406.72131.","journal-title":"J Pharm Bioallied Sci."},{"issue":"2 Pt 1","key":"688_CR6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1542\/peds.110.2.285","volume":"110","author":"BJ Stoll","year":"2002","unstructured":"Stoll BJ, Hansen NI, Adams-Chapman I, Fanaroff AA, Hintz SR, Vohr B, National Institute of Child Health and Human Development Neonatal Research Network, et al. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics. 2002;110(2 Pt 1):285\u201391.","journal-title":"Pediatrics"},{"issue":"4","key":"688_CR7","doi-asserted-by":"publisher","first-page":"e865","DOI":"10.1542\/peds.2009-3412","volume":"126","author":"DK Benjamin Jr","year":"2010","unstructured":"Benjamin DK Jr, Stoll BJ, Gantz MG, Walsh MC, S\u00e1nchez PJ, Das A, et al. Neonatal candidiasis: epidemiology, risk factors, and clinical judgment. Pediatrics. 2010;126(4):e865\u201373. https:\/\/doi.org\/10.1542\/peds.2009-3412.","journal-title":"Pediatrics"},{"issue":"5","key":"688_CR8","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1542\/peds.2005-1996","volume":"117","author":"SK Fridkin","year":"2006","unstructured":"Fridkin SK, Kaufman D, Edwards JR, Shetty S, Horan T. Changing incidence of Candida bloodstream infections among NICU patients in the United States: 1995\u20132004. Pediatrics. 2006;117(5):1680\u20137.","journal-title":"Pediatrics"},{"issue":"2","key":"688_CR9","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1542\/peds.2005-2677","volume":"118","author":"CM Cotten","year":"2006","unstructured":"Cotten CM, Taylor S, Stoll B, Goldberg RN, Hansen NI, S\u00e1nchez PJ, et al. The association of third-generation cephalosporin use and invasive candidiasis in extremely low birth-weight infants. Pediatrics. 2006;118(2):717\u201322.","journal-title":"Pediatrics"},{"issue":"3","key":"688_CR10","doi-asserted-by":"publisher","first-page":"F188","DOI":"10.1136\/adc.2005.082024","volume":"91","author":"L Clerihew","year":"2006","unstructured":"Clerihew L, Lamagni TL, Brocklehurst P, McGuire W. Invasive fungal infection in very low birthweight infants: National Prospective Surveillance Study. Arch Dis Child Fetal Neonatal Ed. 2006;91(3):F188\u201392. https:\/\/doi.org\/10.1136\/adc.2005.082024.","journal-title":"Arch Dis Child Fetal Neonatal Ed"},{"issue":"4","key":"688_CR11","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/00006454-200004000-00011","volume":"19","author":"L Saiman","year":"2000","unstructured":"Saiman L, Ludington E, Pfaller M, Rangel-Frausto S, Wiblin T, Dawson J, et al. Risk factors for candidemia in neonatal intensive care unit patients. Pediatr Infect Dis J. 2000;19(4):319\u201324.","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"688_CR12","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1542\/peds.105.2.438","volume":"105","author":"GL Darmstadt","year":"2000","unstructured":"Darmstadt GL, Dinulos JG, Miller Z. Congenital cutaneous candidiasis: clinical presentation, pathogenesis, and management guidelines. Pediatrics. 2000;105(3):438\u201344.","journal-title":"Pediatrics"},{"issue":"10","key":"688_CR13","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1093\/cid\/cix119","volume":"64","author":"DA Kaufman","year":"2017","unstructured":"Kaufman DA, Coggins SA, Zanelli SA, Weitkamp JH. Congenital cutaneous candidiasis: prompt systemic treatment is associated with improved outcomes in neonates. Clin Infect Dis. 2017;64(10):1387\u201395.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"688_CR14","doi-asserted-by":"publisher","first-page":"e78","DOI":"10.1093\/jpids\/pix113","volume":"7","author":"B Schulz","year":"2018","unstructured":"Schulz B, Welte T, Cornely OA. Neonatal and pediatric candidemia: results from population-based surveillance. J Pediatr Infect Dis Soc. 2018;7(3):e78-85. https:\/\/doi.org\/10.1093\/jpids\/pix113.","journal-title":"J Pediatr Infect Dis Soc."},{"issue":"3","key":"688_CR15","doi-asserted-by":"publisher","first-page":"e01010","DOI":"10.1128\/spectrum.01010-23","volume":"11","author":"FG Menezes","year":"2023","unstructured":"Menezes FG, de Almeida JN. Neonatal invasive candidiasis in low- and middle-income countries. Microbiol Spectr. 2023;11(3):e01010-e1023. https:\/\/doi.org\/10.1128\/spectrum.01010-23.","journal-title":"Microbiol Spectr."},{"issue":"4","key":"688_CR16","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2016","unstructured":"Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62(4):e1-50. https:\/\/doi.org\/10.1093\/cid\/civ933.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"688_CR17","doi-asserted-by":"publisher","first-page":"660","DOI":"10.3390\/pathogens13080660","volume":"13","author":"N Dermitzaki","year":"2024","unstructured":"Dermitzaki N, Baltogianni M, Tsekoura E, Giapros V. Invasive candida infections in neonatal intensive care units: risk factors and new insights in prevention. Pathogens. 2024;13(8):660. https:\/\/doi.org\/10.3390\/pathogens13080660.","journal-title":"Pathogens"},{"issue":"5","key":"688_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/1346-8138.14263","volume":"45","author":"H Kimura","year":"2018","unstructured":"Kimura H, Mitsuto I, Taguchi R, Anzawa K, Mochizuki T. Primary cutaneous aspergillosis caused by Aspergillus tamarii in a premature infant with extremely low birthweight: a case report with short review. J Dermatol. 2018;45(5):622\u20135. https:\/\/doi.org\/10.1111\/1346-8138.14263.","journal-title":"J Dermatol"},{"key":"688_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhin.2018.12.020","volume":"103","author":"AF Talento","year":"2019","unstructured":"Talento AF, Fitzgerald M, Redington B, O\u2019Sullivan N, Fenelon L, Rogers TR. Prevention of healthcare-associated invasive aspergillosis during hospital construction\/renovation works. J Hosp Infect. 2019;103:1\u20132.","journal-title":"J Hosp Infect"},{"issue":"5","key":"688_CR20","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1046\/j.1525-1470.2002.00203.x","volume":"19","author":"CA Woodruff","year":"2002","unstructured":"Woodruff CA, Hebert AA. Neonatal primary cutaneous aspergillosis: case report and review of the literature. Pediatr Dermatol. 2002;19(5):439\u201344. https:\/\/doi.org\/10.1046\/j.1525-1470.2002.00203.x.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"688_CR21","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1086\/514717","volume":"27","author":"AH Groll","year":"1998","unstructured":"Groll AH, Jaeger G, Allendorf A, Herrmann G, Schloesser R, von Loewenich V. Invasive pulmonary aspergillosis in a critically ill neonate: case report and review of invasive aspergillosis during the first 3 months of life. Clin Infect Dis. 1998;27(3):437\u201352. https:\/\/doi.org\/10.1086\/514717.","journal-title":"Clin Infect Dis"},{"issue":"12","key":"688_CR22","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1001\/jamapediatrics.2015.1359","volume":"169","author":"CL Simpson","year":"2015","unstructured":"Simpson CL, Boos MD, Castelo-Soccio L. A crusted papule in a premature neonate: cutaneous fungal infection. JAMA Pediatr. 2015;169(12):1173\u20134. https:\/\/doi.org\/10.1001\/jamapediatrics.2015.1359.","journal-title":"JAMA Pediatr"},{"key":"688_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-204752","author":"B Rogdo","year":"2014","unstructured":"Rogdo B, Kahlert C, Diener PA, Micallef J. Primary cutaneous aspergillosis in a preterm neonate. BMJ Case Rep. 2014. https:\/\/doi.org\/10.1136\/bcr-2014-204752.","journal-title":"BMJ Case Rep"},{"issue":"4","key":"688_CR24","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3109\/15513811003789636","volume":"29","author":"L Roncati","year":"2010","unstructured":"Roncati L, Barbolini G, Fano RA, Rivasi F. Fatal Aspergillus flavus infection in a neonate. Fetal Pediatr Pathol. 2010;29(4):239\u201344. https:\/\/doi.org\/10.3109\/15513811003789636.","journal-title":"Fetal Pediatr Pathol"},{"issue":"11","key":"688_CR25","first-page":"980","volume":"47","author":"SU Phute","year":"2011","unstructured":"Phute SU, Bhakre JB. Aspergillus fumigatus meningitis in a preterm neonate. Indian Pediatr. 2011;47(11):980.","journal-title":"Indian Pediatr"},{"issue":"2","key":"688_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1128\/CMR.00053-10","volume":"24","author":"J Guarner","year":"2011","unstructured":"Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev. 2011;24(2):247\u201380. https:\/\/doi.org\/10.1128\/CMR.00053-10.","journal-title":"Clin Microbiol Rev"},{"issue":"23","key":"688_CR27","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1056\/NEJM198112033052307","volume":"305","author":"RW Redline","year":"1981","unstructured":"Redline RW, Dahms BB. Malassezia pulmonary vasculitis in an infant on long-term intralipid therapy. N Engl J Med. 1981;305(23):1395\u20138. https:\/\/doi.org\/10.1056\/NEJM198112033052307.","journal-title":"N Engl J Med"},{"issue":"3","key":"688_CR28","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1525-1470.2008.00673.x","volume":"25","author":"K Zomorodain","year":"2008","unstructured":"Zomorodain K, Mirhendi H, Tarazooie B, Kordbacheh P, Zeraati H, Nayeri F. Molecular analysis of Malassezia species isolated from hospitalized neonates. Pediatr Dermatol. 2008;25(3):312\u20136. https:\/\/doi.org\/10.1111\/j.1525-1470.2008.00673.x.","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"688_CR29","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/0732-8893(87)90001-0","volume":"7","author":"MJ Marcon","year":"1987","unstructured":"Marcon MJ, Powell DA. Epidemiology, diagnosis, and management of Malassezia furfur systemic infection. Diagn Microbiol Infect Dis. 1987;7(3):161\u201375. https:\/\/doi.org\/10.1016\/0732-8893(87)90001-0.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"688_CR30","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1086\/323335","volume":"34","author":"S Ascioglu","year":"2002","unstructured":"Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7\u201314. https:\/\/doi.org\/10.1086\/323335.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"688_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/j.diagmicrobio.2018.05.015","volume":"92","author":"P Honnavar","year":"2018","unstructured":"Honnavar P, Ghosh AK, Paul S, et al. Identification of Malassezia species by MALDI-TOF MS after expansion of database. Diagn Microbiol Infect Dis. 2018;92(2):118\u201323. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.05.015.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"3","key":"688_CR32","doi-asserted-by":"publisher","first-page":"430","DOI":"10.4103\/0377-4929.42552","volume":"49","author":"K Agarwal","year":"2006","unstructured":"Agarwal K, Sharma M, Singh S, Jain M. Antemortem diagnosis of gastrointestinal mucormycosis in neonates: report of two cases and review of literature. Indian J Pathol Microbiol. 2006;49(3):430\u20132.","journal-title":"Indian J Pathol Microbiol"},{"issue":"11","key":"688_CR33","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1053\/jpsu.2002.36193","volume":"37","author":"D Oh","year":"2002","unstructured":"Oh D, Notrica D. Primary cutaneous mucormycosis in infants and neonates: case report and review of the literature. J Pediatr Surg. 2002;37(11):1607\u201311. https:\/\/doi.org\/10.1053\/jpsu.2002.36193.","journal-title":"J Pediatr Surg"},{"issue":"12","key":"688_CR34","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1038\/sj.jp.7211186","volume":"24","author":"SC Diven","year":"2004","unstructured":"Diven SC, Angel CA, Hawkins HK, Rowen JL, Shattuck KE. Intestinal zygomycosis due to Absidia corymbifera mimicking necrotizing enterocolitis in a preterm neonate. J Perinatol. 2004;24(12):794\u20136. https:\/\/doi.org\/10.1038\/sj.jp.7211186.","journal-title":"J Perinatol"},{"issue":"1","key":"688_CR35","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1055\/s-2007-993895","volume":"15","author":"N Linder","year":"1998","unstructured":"Linder N, Keller N, Huri C, Kuint J, Goldshmidt-Reuven A, Barzilai A. Primary cutaneous mucormycosis in a premature infant: case report and review of the literature. Am J Perinatol. 1998;15(1):35\u20138. https:\/\/doi.org\/10.1055\/s-2007-993895.","journal-title":"Am J Perinatol"},{"issue":"1","key":"688_CR36","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1542\/peds.78.1.100","volume":"78","author":"CB White","year":"1986","unstructured":"White CB, Barcia PJ, Bass JW. Neonatal zygomycotic necrotizing cellulitis. Pediatrics. 1986;78(1):100\u20132.","journal-title":"Pediatrics"},{"issue":"5","key":"688_CR37","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/s0022-3476(80)80550-6","volume":"96","author":"JE Dennis","year":"1980","unstructured":"Dennis JE, Rhodes KH, Cooney DR, Roberts GD. Nosocomial Rhizopus infection (zygomycosis) in children. J Pediatr. 1980;96(5):824\u20138. https:\/\/doi.org\/10.1016\/s0022-3476(80)80550-6.","journal-title":"J Pediatr"},{"issue":"2","key":"688_CR38","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1525-1470.2009.00941.x","volume":"27","author":"A Metkar","year":"2010","unstructured":"Metkar A, Joshi A, Vishalakshi V, Miskeen AK, Torsekar RG. Extensive neonatal dermatophytoses. Pediatr Dermatol. 2010;27(2):189\u201391. https:\/\/doi.org\/10.1111\/j.1525-1470.2009.00941.x.","journal-title":"Pediatr Dermatol"},{"issue":"4","key":"688_CR39","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1128\/JCM.39.4.1608-1611.2001","volume":"39","author":"MF Cheng","year":"2001","unstructured":"Cheng MF, Chiou CC, Liu YC, Wang HZ, Hsieh KS. Cryptococcus laurentii fungemia in a premature neonate. J Clin Microbiol. 2001;39(4):1608\u201311. https:\/\/doi.org\/10.1128\/JCM.39.4.1608-1611.2001.","journal-title":"J Clin Microbiol"},{"key":"688_CR40","doi-asserted-by":"crossref","unstructured":"Maldonado YA. Pneumocystis and other less common fungal infections. Infect Dis Fetus Newborn Infant. 2010;1078\u20131123.","DOI":"10.1016\/B978-1-4160-6400-8.00034-1"},{"issue":"4","key":"688_CR41","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/00006454-198307000-00012","volume":"2","author":"EA Watts","year":"1983","unstructured":"Watts EA, Gard PD Jr, Tuthill SW. First reported case of intrauterine transmission of blastomycosis. Pediatr Infect Dis. 1983;2(4):308\u201310. https:\/\/doi.org\/10.1097\/00006454-198307000-00012.","journal-title":"Pediatr Infect Dis"},{"issue":"2","key":"688_CR42","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.clp.2010.04.001","volume":"37","author":"JL Wynn","year":"2010","unstructured":"Wynn JL, Levy O. Role of innate host defenses in susceptibility to early-onset neonatal sepsis. Clin Perinatol. 2010;37(2):307\u201337. https:\/\/doi.org\/10.1016\/j.clp.2010.04.001.","journal-title":"Clin Perinatol"},{"issue":"5","key":"688_CR43","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jaad.2009.02.052","volume":"61","author":"D Marcoux","year":"2009","unstructured":"Marcoux D, Jafarian F, Joncas V, et al. Deep cutaneous fungal infections in immunocompromised children. J Am Acad Dermatol. 2009;61(5):857\u201364. https:\/\/doi.org\/10.1016\/j.jaad.2009.02.052.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"688_CR44","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1128\/CMR.17.3.638-680.2004","volume":"17","author":"D Kaufman","year":"2004","unstructured":"Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17(3):638\u201380. https:\/\/doi.org\/10.1128\/CMR.17.3.638-680.2004.","journal-title":"Clin Microbiol Rev"},{"key":"688_CR45","doi-asserted-by":"publisher","first-page":"S59","DOI":"10.1016\/j.jped.2020.10.006","volume":"97","author":"MI Moraes-Pinto","year":"2021","unstructured":"Moraes-Pinto MI, Suano-Souza F, Aranda CS. Immune system: development and acquisition of immunological competence. J Pediatr. 2021;97:S59-66. https:\/\/doi.org\/10.1016\/j.jped.2020.10.006.","journal-title":"J Pediatr"},{"key":"688_CR46","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.3389\/fimmu.2019.01089","volume":"10","author":"NE Stevens","year":"2019","unstructured":"Stevens NE, Glombitza S, Weidinger S. Skin barrier and autoimmunity: mechanisms and novel therapeutic approaches for autoimmune blistering diseases of the skin. Front Immunol. 2019;10:1089. https:\/\/doi.org\/10.3389\/fimmu.2019.01089.","journal-title":"Front Immunol"},{"key":"688_CR47","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1038\/s41390-021-01842-7","volume":"91","author":"KED Weimer","year":"2022","unstructured":"Weimer KED, Smith PB, Puia-Dumitrescu M, et al. Invasive fungal infections in neonates: a review. Pediatr Res. 2022;91:404\u201312. https:\/\/doi.org\/10.1038\/s41390-021-01842-7.","journal-title":"Pediatr Res"},{"issue":"2","key":"688_CR48","doi-asserted-by":"publisher","first-page":"119","DOI":"10.4161\/viru.22913","volume":"4","author":"FL Mayer","year":"2013","unstructured":"Mayer FL, Wilson D, Hube B. Candida albicans pathogenicity mechanisms. Virulence. 2013;4(2):119\u201328. https:\/\/doi.org\/10.4161\/viru.22913.","journal-title":"Virulence."},{"issue":"4","key":"688_CR49","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.riam.2010.10.003","volume":"27","author":"A Abad","year":"2010","unstructured":"Abad A, Fern\u00e1ndez-Molina V, Bikandi J, et al. What makes Aspergillus fumigatus a successful pathogen? Genes and molecules involved in invasive aspergillosis. Rev Iberoam Micol. 2010;27(4):155\u201382. https:\/\/doi.org\/10.1016\/j.riam.2010.10.003.","journal-title":"Rev Iberoam Micol"},{"key":"688_CR50","doi-asserted-by":"crossref","unstructured":"Kimberlin DW, Barnett ED, Lynfield R, Sawyer MH. Candidiasis. Red book: 2021\u20132024. Report of the Committee on Infectious Diseases. 32nd ed. American Academy of Pediatrics; 2021. p. 246.","DOI":"10.1542\/9781610025225"},{"issue":"12","key":"688_CR51","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/nejmra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157\u201367. https:\/\/doi.org\/10.1056\/nejmra035092.","journal-title":"N Engl J Med"},{"issue":"8","key":"688_CR52","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1517\/17425255.2011.577739","volume":"7","author":"SN de Wildt","year":"2011","unstructured":"de Wildt SN. Profound changes in drug metabolism enzymes and possible effects on drug therapy in neonates and children. Expert Opin Drug Metab Toxicol. 2011;7(8):935\u201348. https:\/\/doi.org\/10.1517\/17425255.2011.577739.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"9","key":"688_CR53","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1086\/503043","volume":"42","author":"WE Dismukes","year":"2006","unstructured":"Dismukes WE. Antifungal therapy: lessons learned over the past 27 years. Clin Infect Dis. 2006;42(9):1289\u201396. https:\/\/doi.org\/10.1086\/503043.","journal-title":"Clin Infect Dis"},{"key":"688_CR54","doi-asserted-by":"publisher","unstructured":"Escribano P, Mesquida A, L\u00f3pez-Montesinos S, et al. Amphotericin B, itraconazole, posaconazole, and isavuconazole MICs against clinical Mucorales isolates obtained by visual inspection and spectrophotometric reading according to the EUCAST 9.4 procedure. Med Mycol. 2023;61(5):myad045. https:\/\/doi.org\/10.1093\/mmy\/myad045.","DOI":"10.1093\/mmy\/myad045"},{"issue":"5","key":"688_CR55","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1097\/INF.0b013e3182467a72","volume":"31","author":"SB Ascher","year":"2012","unstructured":"Ascher SB, Smith PB, Watt K, Benjamin DK, Cohen-Wolkowiez M, Clark RH, et al. Antifungal therapy and outcomes in infants with invasive Candida infections. Pediatr Infect Dis J. 2012;31(5):439\u201343. https:\/\/doi.org\/10.1097\/INF.0b013e3182467a72.","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"688_CR56","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1128\/AAC.49.12.5092-5098.2005","volume":"49","author":"G W\u00fcrthwein","year":"2005","unstructured":"W\u00fcrthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemorther. 2005;49(12):5092\u20138. https:\/\/doi.org\/10.1128\/AAC.49.12.5092-5098.2005.","journal-title":"Antimicrob Agents Chemorther."},{"issue":"1","key":"688_CR57","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1128\/AAC.00446-06","volume":"51","author":"P Schwarz","year":"2007","unstructured":"Schwarz P, Janbon G, Dromer F, Lortholary O, Dannaoui E. Combination of amphotericin B with flucytosine is active in vitro against flucytosine-resistant isolates of Cryptococcus neoformans. Antimicrob Agents Chemother. 2007;51(1):383\u20135.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"688_CR58","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1086\/514669","volume":"27","author":"DR Hospenthal","year":"1998","unstructured":"Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis. 1998;27(2):260\u20134. https:\/\/doi.org\/10.1086\/514669.","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"688_CR59","first-page":"i13","volume":"65","author":"WW Hope","year":"2010","unstructured":"Hope WW, Tabernero L, Robbins J, Denning DW. An overview of the role of pharmacokinetics and pharmacodynamics in antifungal drug therapy. J Antimicrob Chemother. 2010;65(Suppl. 1):i13-24.","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"688_CR60","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1046\/j.1365-280X.1999.00245.x","volume":"37","author":"RB Caligiorne","year":"1999","unstructured":"Caligiorne RB, Resende MA, Melillo PH, Peluso CP, Carmo FH, Azevedo V. In vitro susceptibility of chromoblastomycosis and phaeohyphomycosis agents to antifungal drugs. Med Mycol. 1999;37(6):405\u20139.","journal-title":"Med Mycol"},{"key":"688_CR61","unstructured":"Antimicrobe. Management of specific infectious diseases. 2007. http:\/\/www.antimicrobe.org\/f05rev.asp. Accessed 19 Feb 2025."},{"issue":"5","key":"688_CR62","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1159\/000007307","volume":"46","author":"A Vermes","year":"2000","unstructured":"Vermes A, Guchelaar HJ, Dankert J. Prediction of flucytosine-induced thrombocytopenia using creatinine clearance. Chemotherapy. 2000;46(5):335\u201341.","journal-title":"Chemotherapy"},{"key":"688_CR63","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/204237","volume":"2013","author":"C Spampinato","year":"2013","unstructured":"Spampinato C, Leonardi D. Candida infections, causes, targets, and resistance mechanisms: traditional and alternative antifungal agents. Biomed Res Int. 2013;2013: 204237.","journal-title":"Biomed Res Int"},{"issue":"6","key":"688_CR64","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3109\/09273948.2010.507320","volume":"18","author":"GN Magrath","year":"2010","unstructured":"Magrath GN, Pulido JS, Montero J, Mason C, Wilson J. Cystoid macular edema secondary to fluconazole toxicity. Ocul Immunol Inflamm. 2010;18(6):472\u20134.","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"688_CR65","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/clpt.1993.147","volume":"54","author":"H Sax\u00e9n","year":"1993","unstructured":"Sax\u00e9n H, Hoppu K, Pohjavuori M. Pharmacokinetics of fluconazole in very low birth weight infants during the first two weeks of life. Clin Pharmacol Ther. 1993;54(3):269\u201377.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"688_CR66","doi-asserted-by":"publisher","first-page":"4043","DOI":"10.1128\/AAC.00569-08","volume":"52","author":"KC Wade","year":"2008","unstructured":"Wade KC, Wu D, Kaufman DA, Ward RM, Benjamin DK Jr, Sullivan JE, et al. Population pharmacokinetics of fluconazole in young infants. Antimicrob Agents Chemother. 2008;52(11):4043\u20139.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"688_CR67","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF03190361","volume":"24","author":"MC Nahata","year":"1999","unstructured":"Nahata MC, Tallian KB, Force RW. Pharmacokinetics of fluconazole in young infants. Eur J Drug Metab Pharmacokinet. 1999;24(2):155\u20137.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"7","key":"688_CR68","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1002\/psp4.12414","volume":"8","author":"JG Gerhart","year":"2019","unstructured":"Gerhart JG, Watt KM, Edginton A, Wade KC, Salerno SN, Benjamin DK, et al. Physiologically-based pharmacokinetic modeling of fluconazole using plasma and cerebrospinal fluid samples from preterm and term infants. CPT Pharmacometr Syst Pharmacol. 2019;8(7):500\u201310.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"1","key":"688_CR69","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/cpt.1990","volume":"109","author":"SN Salerno","year":"2021","unstructured":"Salerno SN, Edginton A, Gerhart JG, Laughon MM, Ambalavanan N, Sokol GM, et al. Physiologically-based pharmacokinetic modeling characterizes the CYP3A-mediated drug-drug interaction between fluconazole and sildenafil in infants. Clin Pharmacol Ther. 2021;109(1):253\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"688_CR70","first-page":"1","volume":"6","author":"SP Hawser","year":"2009","unstructured":"Hawser SP, Norris H, Jessup C. Micafungin (APX001): a novel antifungal agent. J Fungi. 2009;6(3):1\u201311.","journal-title":"J Fungi."},{"issue":"5","key":"688_CR71","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1097\/INF.0b013e3181910e2d","volume":"28","author":"PB Smith","year":"2009","unstructured":"Smith PB, Walsh TJ, Hope W, et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J. 2009;28(5):412\u20135. https:\/\/doi.org\/10.1097\/INF.0b013e3181910e2d.","journal-title":"Pediatr Infect Dis J"},{"key":"688_CR72","unstructured":"Micafungin: uses, interactions, mechanism of action. DrugBank. 2024. https:\/\/go.drugbank.com\/drugs\/DB01141. Accessed 18 Feb 2025."},{"key":"688_CR73","unstructured":"High-dose micafungin for preterm neonates and infants with systemic candidiasis. PMC. 2016. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5119014. Accessed 18 Feb 2025."},{"key":"688_CR74","doi-asserted-by":"publisher","unstructured":"Plasma and cerebrospinal fluid concentrations of micafungin in preterm and term neonates with invasive candidiasis. MDPI. 2023. https:\/\/doi.org\/10.3390\/ph16030472.","DOI":"10.3390\/ph16030472"},{"issue":"9390","key":"688_CR75","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/S0140-6736(03)14472-8","volume":"362","author":"DW Denning","year":"2003","unstructured":"Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142\u201351.","journal-title":"Lancet"},{"issue":"10","key":"688_CR76","first-page":"2611","volume":"75","author":"LM Lopez-Soria","year":"2020","unstructured":"Lopez-Soria LM, Kantecki M, Perfect JR. Rezafungin: a new long-acting echinocandin antifungal. J Antimicrob Chemother. 2020;75(10):2611\u201321.","journal-title":"J Antimicrob Chemother"},{"key":"688_CR77","unstructured":"US FDA. Rezzayo (rezafungin) injection, for intravenous use. 2022. https:\/\/www.fda.gov. Accessed 18 Feb 2025."},{"issue":"7","key":"688_CR78","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s00431-019-03382-z","volume":"178","author":"N Linder","year":"2019","unstructured":"Linder N, et al. Treatment of invasive fungal infections in neonates. Eur J Pediatr. 2019;178(7):995\u20131002.","journal-title":"Eur J Pediatr"},{"issue":"4","key":"688_CR79","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s12519-016-0034-x","volume":"12","author":"S Chen","year":"2016","unstructured":"Chen S, Sun KY, Feng XW, Ran X, Lama J, Ran YP. Efficacy and safety of itraconazole use in infants. World J Pediatr. 2016;12(4):399\u2013407. https:\/\/doi.org\/10.1007\/s12519-016-0034-x.","journal-title":"World J Pediatr."},{"issue":"2","key":"688_CR80","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1128\/AAC.42.2.404","volume":"42","author":"L de Repentigny","year":"1998","unstructured":"de Repentigny L, Ratelle J, Leclerc JM, Cornu G, Sokal EM, Jacqmin P, et al. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother. 1998;42(2):404\u20138. https:\/\/doi.org\/10.1128\/AAC.42.2.404.","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"688_CR81","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1111\/bcp.12025","volume":"75","author":"JM Lestner","year":"2012","unstructured":"Lestner JM, Smith PB, Cohen-Wolkowiez M, Benjamin DK Jr, Hope WW. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. Br J Clin Pharmacol. 2012;75(6):1358\u201380. https:\/\/doi.org\/10.1111\/bcp.12025.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"688_CR82","first-page":"39","volume":"3","author":"JC Unni","year":"2021","unstructured":"Unni JC. Use of antifungals other than amphotericin B for invasive fungal infections in neonates and children. Pediatr Infect Dis. 2021;3(1):39\u201341.","journal-title":"Pediatr Infect Dis"},{"issue":"5","key":"688_CR83","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1128\/AAC.45.5.1561-1564.2001","volume":"45","author":"C Schmitt","year":"2001","unstructured":"Schmitt C, Perel Y, Harousseau JL, Lemerle S, Chwetzoff E, Le Moing JP, et al. Pharmacokinetics of itraconazole oral solution in neutropenic children during long-term prophylaxis. Antimicrob Agents Chemother. 2001;45(5):1561\u20134. https:\/\/doi.org\/10.1128\/AAC.45.5.1561-1564.2001.","journal-title":"Antimicrob Agents Chemother"},{"key":"688_CR84","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/aac.00297-07","volume":"51","author":"SM Abdel-Rahman","year":"2007","unstructured":"Abdel-Rahman SM, Jacobs RF, Massarella J, Kauffman RE, Bradley JS, Kimko HC, et al. Single-dose pharmacokinetics of intravenous itraconazole and hydroxypropyl-\u03b2-cyclodextrin in infants, children, and adolescents. Antimicrob Agents Chemother. 2007;51:1\u201310. https:\/\/doi.org\/10.1128\/aac.00297-07.","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"688_CR85","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1093\/jac\/dkad269","volume":"78","author":"OA Cornely","year":"2023","unstructured":"Cornely OA, Ostermann H, Koehler P, Teschner D, Limburg E, Kramer WG, et al. Phase 1b safety and pharmacokinetics of intravenous and oral fosmanogepix in patients with acute myeloid leukaemia and neutropenia. J Antimicrob Chemother. 2023;78(11):2645\u201352. https:\/\/doi.org\/10.1093\/jac\/dkad269.","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"688_CR86","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.59210","volume":"16","author":"A Almajid","year":"2024","unstructured":"Almajid A, Bazroon A, Al-Awami HM, Albarbari H, Alqahtani I, Almutairi R, et al. Fosmanogepix: the novel anti-fungal agent\u2019s comprehensive review of in vitro, in vivo, and current insights from advancing clinical trials. Cureus. 2024;16(4): e59210. https:\/\/doi.org\/10.7759\/cureus.59210.","journal-title":"Cureus."},{"key":"688_CR87","doi-asserted-by":"publisher","unstructured":"Goggin KP, Londeree J, Freeman AF, Garro R, George RP. Successful use of fosmanogepix for treatment of rare highly resistant cutaneous fusariosis in a pediatric patient with STAT3 hyper-immunoglobulin E syndrome and end-stage kidney disease. Open Forum Infect Dis. 2023;10(6):ofad285. https:\/\/doi.org\/10.1093\/ofid\/ofad285.","DOI":"10.1093\/ofid\/ofad285"},{"key":"688_CR88","doi-asserted-by":"publisher","unstructured":"Hsu AJ, Hanisch BR, Fisher BT, Huppler AR. Pipeline of novel antifungals for invasive fungal disease in transplant recipients: a pediatric perspective. J Pediatr Infect Dis Soc. 2024;13(Suppl_1):S68\u201379. https:\/\/doi.org\/10.1093\/jpids\/piad115.","DOI":"10.1093\/jpids\/piad115"},{"issue":"15","key":"688_CR89","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","volume":"81","author":"M Hoenigl","year":"2021","unstructured":"Hoenigl M, Sprute R, Egger M, Arastehfar A, Cornely OA, Krause R, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, ooorofim, opelconazole, and rezafungin. Drugs. 2021;81(15):1703\u201329. https:\/\/doi.org\/10.1007\/s40265-021-01611-0.","journal-title":"Drugs"},{"issue":"4","key":"688_CR90","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1007\/s100960100541","volume":"20","author":"C Klingenberg","year":"2001","unstructured":"Klingenberg C, Bode U. Pharmacokinetics of amphotericin B in neonates and infants. Eur J Clin Microbiol Infect Dis. 2001;20(4):265\u201370. https:\/\/doi.org\/10.1007\/s100960100541.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"688_CR91","doi-asserted-by":"publisher","first-page":"5092","DOI":"10.1128\/AAC.49.12.5092-5098.2005","volume":"49","author":"G W\u00fcrthwein","year":"2005","unstructured":"W\u00fcrthwein G, Groll AH, Hempel G, Adler-Shohet FC, Lieberman JM, Walsh TJ. Population pharmacokinetics of amphotericin B lipid complex in neonates. Antimicrob Agents Chemother. 2005;49(12):5092\u20138. https:\/\/doi.org\/10.1128\/AAC.49.12.5092-5098.2005.","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"688_CR92","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1097\/INF.0b013e3181af6201","volume":"28","author":"J Le","year":"2009","unstructured":"Le J, Adler-Shohet FC, Nguyen C, Lieberman JM. Nephrotoxicity associated with amphotericin B deoxycholate in neonates. Pediatr Infect Dis J. 2009;28(12):1061\u20133. https:\/\/doi.org\/10.1097\/INF.0b013e3181af6201.","journal-title":"Pediatr Infect Dis J"},{"issue":"Suppl. 3","key":"688_CR93","doi-asserted-by":"publisher","first-page":"S318","DOI":"10.1093\/clinids\/12.Supplement_3.S318","volume":"12","author":"KW Brammer","year":"1990","unstructured":"Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis. 1990;12(Suppl. 3):S318\u201326.","journal-title":"Rev Infect Dis"},{"issue":"5","key":"688_CR94","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/s0022-3476(05)82674-5","volume":"116","author":"JE Baley","year":"1990","unstructured":"Baley JE, Meyers C, Kliegman RM, Jacobs MR, Blumer JL. Pharmacokinetics, outcome of treatment, and toxic effects of amphotericin B and 5-fluorocytosine in neonates. J Pediatr. 1990;116(5):791\u20137. https:\/\/doi.org\/10.1016\/s0022-3476(05)82674-5.","journal-title":"J Pediatr"},{"key":"688_CR95","unstructured":"South Eastern Sydney Local Health District. Flucytosine ANMF guideline (v1.0). Royal Hospital for Women. 2023. https:\/\/www.seslhd.health.nsw.gov.au\/sites\/default\/files\/groups\/Royal_Hospital_for_Women\/Neonatal\/Neomed\/Flucytosine_ANMFv1.0_20230406.pdf. Accessed 18 Feb 2025."},{"issue":"11","key":"688_CR96","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1038\/jp.2009.75","volume":"29","author":"G Natarajan","year":"2009","unstructured":"Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol. 2009;29(11):738\u201343. https:\/\/doi.org\/10.1038\/jp.2009.75.","journal-title":"J Perinatol"},{"key":"688_CR97","unstructured":"DrugBank Online. Flucytosine (DB01141). https:\/\/go.drugbank.com\/drugs\/DB01141. Accessed 28 Jan 2025."},{"issue":"11","key":"688_CR98","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1097\/INF.0000000000000434","volume":"33","author":"P Manzoni","year":"2014","unstructured":"Manzoni P, Wu C, Tweddle L, Roilides E. Micafungin in premature and non-premature infants: a systematic review of 9 clinical trials. Pediatr Infect Dis J. 2014;33(11):e291\u20138. https:\/\/doi.org\/10.1097\/INF.0000000000000434.","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"688_CR99","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1093\/tropej\/fmh077","volume":"51","author":"P Alexander","year":"2005","unstructured":"Alexander P, Alladi A, Correa M, D\u2019Cruz AJ. Neonatal colonic mucormycosis: a tropical perspective. J Trop Pediatr. 2005;51(1):54\u20139. https:\/\/doi.org\/10.1093\/tropej\/fmh077.","journal-title":"J Trop Pediatr"},{"issue":"6","key":"688_CR100","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1093\/cid\/ciw360","volume":"63","author":"JN Galgiani","year":"2016","unstructured":"Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63(6):e112\u201346. https:\/\/doi.org\/10.1093\/cid\/ciw360.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"688_CR101","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1086\/649858","volume":"50","author":"JR Perfect","year":"2010","unstructured":"Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2010;50(3):291\u2013322. https:\/\/doi.org\/10.1086\/649858.","journal-title":"Clin Infect Dis"},{"key":"688_CR102","unstructured":"Centers for Disease Control and Prevention. Public Health Image Library (PHIL). 2025. https:\/\/phil.cdc.gov\/Details.aspx?pid=15680. Accessed 26 Jan 2025."},{"issue":"9","key":"688_CR103","doi-asserted-by":"publisher","first-page":"551","DOI":"10.3928\/00904481-20100825-05","volume":"39","author":"A Florens","year":"2010","unstructured":"Florens A, Maggiolino G, Kamat M, Joseph T, Piette W, Pyati S. A full-term infant with rash at birth. Pediatr Ann. 2010;39(9):551\u20134. https:\/\/doi.org\/10.3928\/00904481-20100825-05.","journal-title":"Pediatr Ann"},{"key":"688_CR104","unstructured":"Centers for Disease Control and Prevention. Public Health Image Library (PHIL). 2025. https:\/\/phil.cdc.gov\/Details.aspx?pid=23077. Accessed 26 Jan 2025."},{"key":"688_CR105","doi-asserted-by":"publisher","unstructured":"Rogdo B, Kahlert C, Diener PA, Micallef J. Primary cutaneous aspergillosis in a preterm neonate. BMJ Case Reports. 2014. https:\/\/doi.org\/10.1136\/bcr-2014-204752.","DOI":"10.1136\/bcr-2014-204752"},{"key":"688_CR106","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.epsc.2018.05.018","volume":"35","author":"D Brooks","year":"2018","unstructured":"Brooks D, Shahab A, Davies H, Aldrich A, Bedrnicek J, Gollehon N. Invasive cutaneous mucormycosis in an extremely preterm infant. J Pediatr Surg Case Rep. 2018;35:52\u20136.","journal-title":"J Pediatr Surg Case Rep"},{"key":"688_CR107","unstructured":"PathologyOutlines.com. Zygomycetes. 2021. https:\/\/www.pathologyoutlines.com\/topic\/microbiologyzygomycetes.html. Accessed 18 Feb 2025."}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00688-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00688-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T14:58:57Z","timestamp":1750777137000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00688-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["688"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00688-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"9 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review was supported by funds made available through the Office of Faculty Research and Development of the Burnett School of Medicine at Texas Christian University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Lucy Eletel, Talia Thomas, and Emily A. Berry have no conflicts of interest that are directly relevant to the content of this article. Gregory L. Kearns is a consultant in pediatric clinical pharmacology for Tellus Therapeutics, a US corporation engaged in drug development for neonates.\u00a0Gregory L. Kearns is an Editorial Board member of Pediatric Drugs. Professor Kearns was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The literature search engines used to support the development of this work were PubMed Central and EMBASE. An artificial intelligence search engine (ChatGPT v4.0) was used to assist in the creation of the data table.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Under the guidance of GLK and EAB, LE and TT were responsible for creating the first draft of the manuscript. EAB and GLK provided additional content to the paper and were responsible for the final editing prior to submission.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}